Carfilzomib formulation for stable dilution
Patent Information
- Application Number
- JP2022562673
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-12
- Filing Date
- 2021-04-15
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-04-15
AI Technical Summary
The development of a cost-effective, room-temperature-stable injectable formulation of carfilzomib is challenging due to its sensitivity to degradation, and existing formulations require complex reconstitution and have stability issues, leading to impurities and decreased potency.
A room temperature stable diluent injectable formulation of carfilzomib or a pharmaceutically acceptable derivative is developed, comprising carfilzomib, solvents, and optional excipients like surfactants, antioxidants, and buffers, with a method of mixing components to form a reconstituted diluent solution that maintains stability for at least one month at 25°C with minimal impurities.
The formulation achieves stability at room temperature with low impurity levels, simplifying reconstitution and ensuring effective drug potency, suitable for treating multiple myeloma with improved ease of administration and storage.
Abstract
Description
[Technical Field]
[0001] The present invention provides a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable derivative thereof. The present invention further relates to a method for treating patients with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for dilution, wherein component 1 is stored at room temperature for at least one month. [Background technology]
[0002] Carfilzomib is a selective proteasome inhibitor indicated for the treatment of multiple myeloma. Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active site of the 20S proteasome, the proteolytic core particle within the 26S proteasome.
[0003] Carfilzomib is commercially available under the name Kyprolis® in single-dose vials containing 10 mg, 30 mg, and 60 mg of active ingredient. Each vial contains lyophilized carfilzomib, sulfobutyl ether beta-cyclodextrin, citric acid, and sodium hydroxide for pH adjustment.
[0004] A problem with commercially available formulations is that reconstitution of lyophilized products is complex and tedious. The reconstitution process is complicated and requires aseptic reconstitution of each vial by slowly injecting sterile water for injection through the stopper, directing the water against the vial's inner wall to ensure minimal foam formation. If foam occurs, the patient must wait until it settles and the solution becomes clear. Furthermore, visual inspection of the solution before administration is crucial for reconstituted products, and any reconstituted solution that appears to be discolored or contains particulate matter must be discarded. Furthermore, the presence of excess foam is known to lead to reduced potency. Efforts have been made to obtain improved carfilzomib compositions. For example, substituted cyclodextrin additives have been investigated to enhance the solubility of carfilzomib. Summary of the Invention [Problem to be solved by the invention]
[0005] Because carfilzomib is sensitive to degradation, developing a cost-effective, room-temperature stable injectable formulation of carfilzomib has been extremely challenging. There remains a need for improved formulations of carfilzomib with improved ease of manufacture, method of administration, and stability over time, especially when stored at room temperature. [Means for solving the problem]
[0006] An object of the present invention is to provide an injectable formulation for dilution that is stable at room temperature and comprises carfilzomib or a pharmaceutically acceptable derivative thereof. Another object of the present invention is to provide a method of treating patients with multiple myeloma by administering an injectable formulation for dilution that is stable at room temperature and comprises carfilzomib or a pharmaceutically acceptable derivative thereof. It is a further object of the present invention to provide a method for treating patients with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle and administering the reconstituted diluent solution, wherein the reconstituted diluent comprises a room temperature stable parenteral diluent formulation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent. In one aspect of the present invention, there is provided a room temperature stable formulation of carfilzomib that is stable when stored at 25° C. for at least one month. In one aspect of the invention, there is provided a room temperature stable carfilzomib formulation that is stable for at least one month when stored at 25°C, wherein the formulation contains no more than 6% total impurities, preferably no more than 5%, preferably no more than 4%, preferably no more than 3%, preferably no more than 2%, preferably no more than 1.5%, preferably no more than 1%, preferably no more than 0.5%. DETAILED DESCRIPTION OF THE INVENTION
[0007] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. As used herein, the term "about" refers to a +5% deviation from the value in question. As used herein, the terms "possibly" or "in some cases" refer to whether the event or circumstance described below occurs.
[0008] The formulations of the present invention contain "carfilzomib" or a pharmaceutically acceptable derivative thereof. The pharmaceutically acceptable derivative includes a pharmaceutically acceptable salt, solvate, hydrate, anhydrate, enantiomer, isomer, polymorph, tautomer, or mixture thereof. Pharmaceutically acceptable salts are salts that retain the desired biological activity of the parent compound without imparting undesired toxicological effects. Examples of such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, and nitric acid; salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, methanesulfonic acid, butylenesulfonic acid, naphthalenesulfonic acid, and polygalacturonic acid; salts formed from elemental anions such as chloride, bromide, and iodide; salts formed from metal hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, and magnesium hydroxide; salts formed from metal carbonates such as sodium carbonate, potassium carbonate, calcium carbonate, and magnesium carbonate; salts formed from metal bicarbonates such as sodium bicarbonate and potassium bicarbonate; salts formed from metal sulfates such as sodium sulfate and potassium sulfate; and salts formed from metal nitrates such as sodium nitrate and potassium nitrate.
[0009] "Stable formulation" or "stabilized preparation" refers to a formulation of carfilzomib that has sufficient physical and chemical stability to be stored at a suitable temperature for a reasonable period of time. As used herein, the term "room temperature" refers to a temperature of about 15°C to about 40°C. As used herein, the term "impurities of carfilzomib" refers to any compounds resulting from chemical degradation of carfilzomib. Representative degradation pathways include, but are not limited to, products resulting from amide and / or epoxide hydrolysis, oxidation, epimerization, and oxirane ring opening with various nucleophiles.
[0010] As used herein, the term "for dilution" refers to an injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof that can be administered to a patient after direct combination with an infusion vehicle (e.g., dextrose solution, water for injection, Ringer's solution, isotonic sodium chloride solution, a suitable non-aqueous solvent, or any other infusion vehicle). In certain embodiments, the injectable formulation can be provided as a single vial containing an injectable formulation comprising carfilzomib or a pharmaceutically acceptable derivative thereof. Optionally, the injectable formulation may be further diluted with other suitable excipients before being combined with the infusion vehicle.
[0011] As used herein, the term "Component 1" refers to an injectable formulation for dilution that contains carfilzomib or a pharmaceutically acceptable derivative thereof. As used herein, the term "Component 2" refers to an acidifying agent that is reconstituted with Component 1 to form a reconstituted formulation for dilution, and may optionally be further added to or mixed with the infusion vehicle. Component 2 is used in the form of a clear solution or powder.
[0012] As used herein, the term "reconstituted formulation" refers to a formulation of carfilzomib or a pharmaceutically acceptable derivative thereof obtained after mixing component 1 and component 2 before adding them to the infusion vehicle. As used herein, the term "formulation for dilution" refers to a formulation of carfilzomib or a pharmaceutically acceptable derivative thereof that can be administered directly to a patient without further dilution or processing.
[0013] The formulations of the present invention are injectable formulations. The injectable formulations of carfilzomib or a pharmaceutically acceptable derivative thereof according to the present invention can be administered via any route, including intramuscular, intravenous, or subcutaneous. Preferably, the injectable formulations of the present invention are administered intravenously. The formulations of carfilzomib or a pharmaceutically acceptable derivative thereof can be in the form of a liquid concentrate that can be diluted and used. The injectable formulations can be packaged in conventional sterile vials or other suitable sterile containers.
[0014] In one embodiment, a room temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable derivative thereof contains carfilzomib at a concentration of about 5 mg / mL to about 350 mg / mL. In one embodiment, the concentration of carfilzomib ranges from about 10 mg / mL to about 100 mg / mL, or from about 15 mg / mL to about 60 mg / mL, or from about 10 mg / mL to about 60 mg / mL. In a preferred embodiment, the injectable formulation has carfilzomib at a concentration of about 10 mg / mL or about 60 mg / mL.
[0015] In one embodiment, the present invention provides a room-temperature stable injectable formulation for dilution, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents. In one embodiment, the dilution composition may include one or more solvents selected from ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol, polyethylene glycol, glycerol, dimethylacetamide (DMA), N-methylpyrrolidone, dimethyl sulfoxide (DMSO), diethylene glycol monoethyl ether, caprylocaproyl polyoxyl-8 glyceride, glycofurol, or a mixture thereof. In a preferred embodiment, the formulation may include ethanol, dimethylacetamide, propylene glycol, polyethylene glycol, or a mixture thereof. In one embodiment, the ratio of the amount of one or more solvents to the amount of carfilzomib or a pharmaceutically acceptable derivative thereof used may vary from about 100:1 to 8:1.
[0016] In one embodiment, the room temperature stable injectable formulation of the present invention may optionally include one or more pharmaceutically acceptable excipients such as buffers, surfactants, antioxidants and preservatives. The formulation may contain one or more pharmaceutically acceptable surfactants. Suitable surfactants include anionic surfactants, cationic surfactants, amphoteric surfactants, and nonionic surfactants, and exemplary nonionic surfactants include polyethylene oxides such as PEG 300 or PEG 400. Pharmaceutically acceptable surfactants for this use include polysorbates or polyethoxylated castor oil, polyoxyl 20 stearate, polyoxyl 35 castor oil, poloxamer, polyoxyethylene sorbitan monoisostearate, polyethylene glycol 40 sorbitan diisostearate, polyoxyl 40 hydrogenated castor oil, polysorbates, polysorbate 20, polysorbate 40, polyoxyl 60 stearate, polysorbate 80, polysorbate 60, Poloxamer 331, Polyoxyethylene Fatty Acid Esters, Polyoxyl 40 Castor Oil, Poloxamer 188, Polyoxyethylene Polyoxypropylene 1800, Oleic Acid, Sodium Deoxycholate, Sodium Lauryl Sulfate, Sorbitan Monolaurate, Sorbitan Monooleate, Sorbitan Monopalmitate, Sorbitan Trioleate, N-Carbamoylmethoxypolyethylene Glycol 2000-1, 2-Distearol, Myristic Acid , steareth, stearic acid, polyoxyl 40 stearate, sucrose stearate, tocopherol, synthetic triglyceride, trimyristin, tristearin, magnesium stearate, lecithin, lauryl sulfate, vitamin E, vitamin E-TPGS, egg yolk phospholipids, docusate sodium, dimyristoyl phosphatidylglycerol, dimyristoyl lecithin, capryol 20 (propylene glycol monocaprylate), capryol PGMC (monocaprylate) Propylene glycol monolaurate), deoxycholic acid, cholesterol, Cremophor EL, propylene glycol alginate, Croval A-10 (PEG40 almond glyceride), Labrafil 1944 (oleoyl macrogol-6 glyceride), Labrafil 2125 (linoleoyl macrogol-6 glyceride), Labrasol (caprylocaproyl macrogol-8 glyceride), Lauroglycol 90 (propylene glycol monolaurate),Examples of surfactants include lauroglycol FCC (propylene glycol laurate), calcium stearate, lecithin Centromix E, lecithin Centrophase 152, lecithin Centrol 3F21B, POE26 glycerin, Olepal isostearilic (PEG-6 isostearate), Pullulol diisostearilic (polyglycerol-3-diisostearilic), Pullulol oleate CC, POE20 sorbitan trioleate, Tagat TO (polyoxyethyleneglycerol trioleate), and Soltol (macrogol 15 hydroxystearate). In some embodiments, the surfactant may be present in an amount of about 10% to about 90% of the total weight of the dilution formulation, preferably about 20% to about 80% of the total weight of the dilution formulation, and preferably about 30% to about 60% of the total weight of the dilution formulation.
[0017] The formulation may contain a buffer selected from a mixture of a weak acid and an alkali metal salt (e.g., sodium or potassium) and a conjugate base of the weak acid. Suitable buffers include, for example, those selected from the group consisting of citric acid, acetic acid, maleic acid, phosphoric acid, succinic acid, tartaric acid, ascorbic acid, benzenesulfonic acid, oxalic acid, fumaric acid, gluconic acid, malic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, lacturonic acid, lactic acid, lactobionic acid, edetic acid, gentisic acid, metaphosphoric acid, nitric acid, pentetic acid, glycolic acid, and counterion salts thereof.
[0018] The formulation may include one or more antioxidants selected from butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, and C-tocopherol, DL-tocopherol, C-tocopheryl acetate, C-tocopherol tocopherol polyethylene glycol succinate (vitamin E TPGS), L-cysteine ascorbyl palmitate thioglycolate, sodium metabisulfite (SMBS), ascorbic acid, sodium formaldehyde sulfoxylate, or hydrophilic antioxidants including sodium EDTA and thioglycerol. Most typically, the antioxidant concentration is 0.005% to 5% w / w of the total composition.
[0019] The formulations may include a preservative selected from phenol, thimerosal, chlorobutanol, benzyl alcohol, m-cresol, phenoxyethanol, methylparaben, and propylparaben, typically at a concentration of between 0.001% w / w and about 5% w / w of the total composition, and most typically from about 0.003% w / w to about 2.0% w / w of the total composition.
[0020] The formulation may include an acidifying agent selected from citric acid, acetic acid, maleic acid, phosphoric acid, succinic acid, tartaric acid, ascorbic acid, benzenesulfonic acid, oxalic acid, fumaric acid, gluconic acid, malic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, lacturonic acid, lactic acid, lactobionic acid, edetic acid, gentisic acid, metaphosphoric acid, nitric acid, pentetic acid, and glycolic acid. The purpose of using the acidifying agent of the present invention is to solubilize carfilzomib or a pharmaceutically acceptable salt thereof in the infusion medium by maintaining an acidic pH. Furthermore, the purpose of using the acidifying agent of the present invention is to avoid precipitation of the drug in the infusion medium.
[0021] Specific compounds have been identified as impurities resulting from the degradation of carfilzomib: [acid impurity] (S)-2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentamido)-3-phenylpropanoic acid; [diastereomeric impurity] (S)-4-methyl-N-((R)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)pentamido)-3-phenylpropanoic acid; noacetamido)-4-phenylbutanamide; [Phenol impurity] 2,3,4,5,6-pentafluorophenol; [Diol impurity] (S)-N-((S)-1-(((2R,4S)-1,2-dihydroxy-2,6-dimethyl-3-oxoheptan-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamide)pentanamide; [Chloro impurity] (S)-N-((S)-1-(((2S,4S)-1-chloro-2-hydroxy-2, Stability samples have been analyzed for the following: 6-dimethyl-3-oxoheptan-4-yl)amino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; [N-oxide impurity] 4-((4S,7S,10S,13S)-10-benzyl-7-isobutyl-15-methyl-13-((R)-2-methyloxirane-2-carbonyl)-2,5,8,11-tetraoxo-4-phenethyl-3,6,9,12-tetraazahexadecyl)morpholine-4-oxide.
[0022] In one embodiment, the formulation is stable at room temperature with a total impurity content of 6% or less during storage. In one embodiment, the formulation is stable at room temperature with a total impurity content of 5% or less during storage. In one embodiment, the formulation is stable at room temperature with a total impurity content of 4% or less during storage. In one embodiment, the formulation is stable at room temperature with a total impurity content of 3% or less during storage. In one embodiment, the formulation is stable at room temperature with a total impurity content of 2% or less during storage. In one embodiment, the formulation is stable at room temperature with a total impurity content of 1% or less during storage. In one embodiment, the formulation is stable at room temperature with a total impurity content of 0.5% or less during storage. In one embodiment, the formulation of the invention can have a shelf life that is reasonable for the formulation to have sufficient chemical and physical stability. The shelf life can be selected from at least about 1 month, at least about 3 months, at least about 6 months, at least about 1 year, and at least about 2 years.
[0023] In one embodiment, a room-temperature stable formulation refers to any formulation of carfilzomib that is sufficiently stable to be stored at room temperature, such as about 15°C to about 40°C. Temperatures of about 20°C to about 40°C are preferred, more preferably about 25°C to about 40°C, and most preferably about 20°C to about 25°C. It should be understood that the stability of carfilzomib formulations within the temperature ranges of each embodiment always involves the additional parameter of 60% humidity. In a preferred embodiment of the present invention, the stability of a room-temperature stable formulation can be evaluated after storing the formulation of the present invention in a sealed, sterile container at 60% relative humidity and 25°C.
[0024] In one embodiment, the present invention provides a room-temperature stable carfilzomib formulation that is stable for at least one month when stored at 40°C and 75% relative humidity. In one embodiment, the present invention provides a room-temperature stable carfilzomib formulation that is stable for at least three months when stored at 40°C and 75% relative humidity. In one embodiment, the present invention provides a room-temperature stable carfilzomib formulation that is stable for at least six months when stored at 40°C and 75% relative humidity. In one embodiment, the present invention provides a room-temperature stable carfilzomib formulation that is stable for at least one year when stored at 40°C and 75% relative humidity.
[0025] In one embodiment, the present invention provides a room temperature stable carfilzomib formulation that is stable for at least 2 years when stored at 40°C and 75% relative humidity. The stability of the formulations of the present invention is measured by the amount of total impurities formed at the end of the stability period. In certain embodiments, stability is achieved when impurities formed during the specified stability period are 6% or less, preferably 5% or less, preferably 4% or less, preferably 3% or less, preferably 2% or less, preferably 1.5% or less, preferably 1% or less, and preferably 0.5% or less.
[0026] In one embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition may have a total impurity concentration of 6% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition may have a total impurity concentration of 5% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition may have a total impurity concentration of 4% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition may have a total impurity concentration of 3% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition may have a total impurity concentration of 2% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for one month, the carfilzomib composition may have a total impurity concentration of 1.5% or less by HPLC. In one embodiment, after storage at 75% RH and 40° C. for one month, the carfilzomib composition may have less than 1% total impurities by HPLC. In one embodiment, after storage at 75% RH and 40° C. for one month, the carfilzomib composition may have less than 0.5% total impurities by HPLC.
[0027] In one embodiment, after storage at 75% RH and 40°C for three months, the carfilzomib composition may have a total impurity concentration of 6% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for three months, the carfilzomib composition may have a total impurity concentration of 5% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for three months, the carfilzomib composition may have a total impurity concentration of 4% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for three months, the carfilzomib composition may have a total impurity concentration of 3% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for three months, the carfilzomib composition may have a total impurity concentration of 2% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for three months, the carfilzomib composition may have a total impurity concentration of 1.5% or less by HPLC. In one embodiment, the carfilzomib composition may have less than or equal to 1% total impurities by HPLC after storage for 3 months at 75% RH and 40° C. In one embodiment, the carfilzomib composition may have less than or equal to 0.5% total impurities by HPLC after storage for 3 months at 75% RH and 40° C.
[0028] In one embodiment, after storage at 75% RH and 40°C for six months, the carfilzomib composition may have a total impurity concentration of 6% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for six months, the carfilzomib composition may have a total impurity concentration of 5% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for six months, the carfilzomib composition may have a total impurity concentration of 4% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for six months, the carfilzomib composition may have a total impurity concentration of 3% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for six months, the carfilzomib composition may have a total impurity concentration of 2% or less by HPLC. In one embodiment, after storage at 75% RH and 40°C for six months, the carfilzomib composition may have a total impurity concentration of 1.5% or less by HPLC. In one embodiment, after storage for 6 months at 75% RH and 40° C., the carfilzomib composition may have 1% or less total impurities by HPLC. In one embodiment, after storage for 6 months at 75% RH and 40° C., the carfilzomib composition may have 0.5% or less total impurities by HPLC.
[0029] In one embodiment, the invention provides a room-temperature stable carfilzomib formulation that is stable for at least one month when stored at 25°C and 60% relative humidity. In one embodiment, the invention provides a room-temperature stable carfilzomib formulation that is stable for at least three months when stored at 25°C and 60% relative humidity. In one embodiment, the invention provides a room-temperature stable carfilzomib formulation that is stable for at least six months when stored at 25°C and 60% relative humidity. In one embodiment, the invention provides a room-temperature stable carfilzomib formulation that is stable for at least one year when stored at 25°C and 60% relative humidity.
[0030] In one embodiment, the present invention provides a carfilzomib formulation that is stable at room temperature, and is stable for at least two years when stored at 25°C and 60% relative humidity. This stability of the formulations of the present invention is measured by the amount of total impurities formed at the end of the stability period. In certain embodiments, stability is achieved when impurities formed during the specified stability period are 6% or less, preferably 5% or less, preferably 4% or less, preferably 3% or less, preferably 2% or less, preferably 1.5% or less, preferably 1% or less, and preferably 0.5% or less.
[0031] In one embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition may have a total impurity concentration of 6% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition may have a total impurity concentration of 5% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition may have a total impurity concentration of 4% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition may have a total impurity concentration of 3% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition may have a total impurity concentration of 2% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for one month, the carfilzomib composition may have a total impurity concentration of 1.5% or less by HPLC. In one embodiment, after storage for one month at 60% RH and 25° C., the carfilzomib composition may have less than 1% total impurities by HPLC. In one embodiment, after storage for one month at 60% RH and 25° C., the carfilzomib composition may have less than 0.5% total impurities by HPLC.
[0032] In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition may have a total impurity concentration of 6% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition may have a total impurity concentration of 5% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition may have a total impurity concentration of 4% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition may have a total impurity concentration of 3% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition may have a total impurity concentration of 2% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for three months, the carfilzomib composition may have a total impurity concentration of 1.5% or less by HPLC. In one embodiment, after storage for 3 months at 60% RH and 25° C., the carfilzomib composition may have 1% or less total impurities by HPLC. In one embodiment, after storage for 3 months at 60% RH and 25° C., the carfilzomib composition may have 0.5% or less total impurities by HPLC.
[0033] In one embodiment, after storage at 60% RH and 25°C for six months, the carfilzomib composition may have a total impurity concentration of 6% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for six months, the carfilzomib composition may have a total impurity concentration of 5% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for six months, the carfilzomib composition may have a total impurity concentration of 4% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for six months, the carfilzomib composition may have a total impurity concentration of 3% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for six months, the carfilzomib composition may have a total impurity concentration of 2% or less by HPLC. In one embodiment, after storage at 60% RH and 25°C for six months, the carfilzomib composition may have a total impurity concentration of 1.5% or less by HPLC. In one embodiment, after storage for 6 months at 60% RH and 25° C., the carfilzomib composition may have 1% or less total impurities by HPLC. In one embodiment, after storage for 6 months at 60% RH and 25° C., the carfilzomib composition may have 0.5% or less total impurities by HPLC.
[0034] In one embodiment, the present invention provides an injectable formulation stable at room temperature comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents. In one embodiment, the present invention provides an injectable formulation stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from an antioxidant, a buffering agent, a preservative, and a surfactant. In one embodiment, the present invention provides an injectable formulation stable at room temperature, including a diluent, a ready-to-use formulation, and a liquid concentrate, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents. In a preferred embodiment, the injectable formulation of the present invention includes a solution for diluent that is stable at room temperature. In one embodiment, the present invention provides a room temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents. In one embodiment, the present invention provides a room temperature stable injectable formulation for dilution, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants.
[0035] In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation contains no more than 6% total impurities after a one-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are less than or equal to 5% after a one-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 4% or less after a one-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are less than or equal to 3% after a one-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are less than or equal to 2% after a one-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 1.5% or less after a one-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation contains 1% or less total impurities over a one-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are less than or equal to 0.5% after a one-month shelf life.
[0036] In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature and comprises carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation contains no more than 6% total impurities after one month of storage at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 6% total impurities after one month of storage at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 5% total impurities after one month of storage at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 4% total impurities after one month of storage at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 3% total impurities after one month of storage at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 2% total impurities after a one-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 1.5% total impurities after one month of storage at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains 1% or less total impurities after one month of storage at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains 0.5% or less total impurities after a one-month storage period at 25°C and 60% relative humidity.
[0037] In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation contains no more than 6% total impurities after a shelf life of 3 months. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 5% or less after a shelf life of 3 months. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 4% or less after a 3-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 3% or less after a 3-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are less than or equal to 2% after a shelf life of 3 months. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 1.5% or less after a 3-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 1% or less after a shelf life of 3 months. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are less than or equal to 0.5% after a shelf life of 3 months.
[0038] In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature and comprises carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation contains no more than 6% total impurities after a 3-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 6% total impurities after a 3-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 5% total impurities after a storage period of 3 months at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 4% total impurities after a 3-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 3% total impurities after a 3-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 2% total impurities after a 3-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 1.5% total impurities after a shelf life of 3 months at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains 1% or less total impurities after a storage period of 3 months at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains 0.5% or less total impurities after a shelf life of 3 months at 25°C and 60% relative humidity.
[0039] In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation contains no more than 6% total impurities after a 6-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 5% or less after a shelf life of 6 months. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation contains no more than 4% total impurities after a shelf life of 6 months. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 3% or less after a 6-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are less than or equal to 2% after a shelf life of 6 months. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 1.5% or less after a 6-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 1% or less after a 6-month shelf life. In one embodiment, a room temperature stable injectable formulation for dilution is provided, comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total impurities are 0.5% or less after a six-month shelf life.
[0040] In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature and comprises carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation contains no more than 6% total impurities after a 6-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 6% total impurities after a 6-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 5% total impurities after a 6-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 4% total impurities after a 6-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 3% total impurities after a 6-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 2% total impurities after a 6-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 1.5% total impurities during a 6-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains no more than 1% total impurities after a 6-month storage period at 25°C and 60% relative humidity. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature, comprising carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, preservatives, and surfactants, wherein the formulation contains 0.5% or less total impurities after a 6-month storage period at 25°C and 60% relative humidity.
[0041] Obtaining injectable formulations that are stable at room temperature is always desirable and beneficial, as it offers commercial and handling advantages over formulations stored under harsh conditions such as 2-8° C. However, obtaining injectable formulations that are stable at room temperature and have low impurity levels or impurity levels that are within the limits acceptable by drug approval authorities is extremely challenging.
[0042] During the stability study, it was surprisingly found that the injectable diluent without the acidifying agent had a significantly better impurity profile than the injectable diluent with the acidifying agent. Thus, the acidifying agent adversely affected the stability of the formulation at room temperature, resulting in the generation of more impurities during the stability period compared to the formulation without the acidifying agent. The better impurity profile according to the present invention includes the difference in total impurities obtained during the stability period upon analysis of the formulation samples by HPLC.
[0043] In one embodiment, the present invention provides a room temperature stable injectable formulation comprising carfilzomib or a pharmaceutically acceptable salt thereof that is completely free of acidifying agents. In one embodiment, the present invention provides a room temperature stable injectable formulation comprising carfilzomib and pharmaceutically acceptable salts thereof that is free of any acidifying agents during the stability period of the formulation. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature and comprises carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, and surfactants, but does not contain an acidifying agent during the stability period of the formulation. In one embodiment, the present invention provides an injectable formulation for dilution that is stable at room temperature and comprises carfilzomib or a pharmaceutically acceptable salt thereof, one or more solvents; and, optionally, one or more pharmaceutically acceptable excipients selected from antioxidants, buffers, and surfactants, but does not contain an acidifying agent during the stability period of the formulation.
[0044] One embodiment of the present invention relates to the delivery of an injectable formulation of carfilzomib that is stable at room temperature and that, after dilution to an appropriate injection (particularly infusion, especially intravenous) concentration, can be administered in an appropriate amount to treat carfilzomib-responsive conditions known in the art.
[0045] In one embodiment of the present invention, a method is provided for treating patients with relapsed or refractory multiple myeloma by administering a room temperature stable parenteral formulation of carfilzomib for dilution or a ready-to-use formulation, alone or in combination with dexamethasone or lenalidomide plus dexamethasone.
[0046] One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total amount of impurities during storage is 6% or less. One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total amount of impurities during storage is 5% or less. One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total amount of impurities during storage is 4% or less. One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total amount of impurities during storage is 3% or less. One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total amount of impurities during storage is 2% or less. One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the total amount of impurities during storage is 1.5% or less. One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation has a total impurity content of 1% or less during storage.One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof and one or more solvents, wherein the formulation has a total impurity content of 0.5% or less during storage.
[0047] One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof, which is stable for one month when stored at 25°C and 60% relative humidity. One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof, which is stable for three months when stored at 25°C and 60% relative humidity. One embodiment of the present invention provides a method for treating a patient with relapsed or refractory multiple myeloma, comprising administering a room-temperature stable injectable formulation for dilution comprising carfilzomib or a pharmaceutically acceptable salt thereof, which is stable for six months when stored at 25°C and 60% relative humidity.
[0048] One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent.
[0049] In one embodiment of the present invention, component 2 comprises an acidifying agent, which can be selected from citric acid, malic acid, phosphoric acid, orthophosphoric acid (OPA), fumaric acid, or a mixture thereof. In one embodiment, the ratio of the acidifying agent used to carfilzomib or a pharmaceutically acceptable salt thereof is about 1:50 to about 1:1 on a w / w basis. In one embodiment, the ratio of the acidifying agent used to carfilzomib or a pharmaceutically acceptable salt thereof is about 1:40 to about 1:1 on a w / w basis. In one embodiment, the ratio of the acidifying agent used compared to carfilzomib or a pharmaceutically acceptable salt thereof is about 1:30 to about 1:1 on a w / w basis. In one embodiment, the ratio of the acidifying agent used to carfilzomib or a pharmaceutically acceptable salt thereof is about 1:20 to about 1:1 on a w / w basis. In one embodiment, the ratio of acidifying agent used to carfilzomib or a pharmaceutically acceptable salt thereof is from about 1:10 to about 1:1 on a w / w basis.
[0050] Carfilzomib or a pharmaceutically acceptable salt thereof is susceptible to degradation at room temperature in a dilute parenteral solution when component 2 is added to component 1. In one embodiment, a mixture containing components 1 and 2 should not be used after 4 hours of mixing when the mixture is stored at room temperature. In a preferred embodiment, a mixture containing components 1 and 2 should not be used after 5 hours of mixing when the mixture is stored at room temperature. In a preferred embodiment, a mixture containing components 1 and 2 should not be used after 6 hours of mixing when the mixture is stored at room temperature. In a preferred embodiment, when the mixture is stored at 2 to 8°C, the mixture of component 1 and component 2 should not be used for administration to an infusion medium 24 hours after mixing.
[0051] In one embodiment of the present invention, a method for treating a patient with relapsed or refractory multiple myeloma is provided, comprising mixing component 1 and component 2 to form a reconstituted solution for dilution, and then diluting the reconstituted solution for dilution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation for dilution of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 is not used after 4 hours of mixing when the mixture is stored at room temperature. In one embodiment of the present invention, there is provided a method for treating a patient with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for dilution, and then diluting the reconstituted solution for dilution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation for dilution of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 is not used after 5 hours of mixing when the mixture is stored at room temperature. In one embodiment of the present invention, there is provided a method for treating a patient with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for dilution, and then diluting the reconstituted solution for dilution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation for dilution of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 is not used after 6 hours of mixing when the mixture is stored at room temperature.
[0052] In one embodiment of the present invention, there is provided a method for treating a patient with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for diluent, and then diluting the reconstituted solution for diluent with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation for diluent of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 contains no more than 2% total impurities from mixing up to 4 hours after mixing when the mixture is stored at room temperature. In one embodiment of the present invention, there is provided a method for treating a patient with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for diluent, and then diluting the reconstituted solution for diluent with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation for diluent of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 contains no more than 1% total impurities from mixing up to 4 hours after mixing when the mixture is stored at room temperature. In one embodiment of the present invention, there is provided a method for treating a patient with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for diluent, and then diluting the reconstituted solution for diluent with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation for diluent of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 contains no more than 2% total impurities from mixing up to 5 hours after mixing when the mixture is stored at room temperature. In one embodiment of the present invention, there is provided a method for treating a patient with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for diluent, and then diluting the reconstituted solution for diluent with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation for diluent of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 contains no more than 1% total impurities from mixing up to 5 hours after mixing when the mixture is stored at room temperature. In one embodiment of the present invention, there is provided a method for treating a patient with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for diluent, and then diluting the reconstituted solution for diluent with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation for diluent of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 has no more than 2% total impurities from mixing up to 6 hours after mixing when the mixture is stored at room temperature. In one embodiment of the present invention, there is provided a method for treating a patient with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for diluent, and then diluting the reconstituted solution for diluent with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation for diluent of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 contains no more than 1% total impurities from mixing up to 6 hours after mixing when the mixture is stored at room temperature.
[0053] In one embodiment of the present invention, there is provided a method for treating a patient with relapsed or refractory multiple myeloma, comprising mixing component 1 and component 2 to form a reconstituted solution for dilution, and then diluting the reconstituted solution for dilution with an infusion vehicle, wherein component 1 comprises a room-temperature stable parenteral formulation for dilution of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent, and the mixture comprising components 1 and 2 is not used for administration after 24 hours from mixing when stored at 2-8°C.
[0054] One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof, and component 2 is an acidifying agent.
[0055] One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof for dilution and contains no more than 6% total impurities during a 6-month storage period at 25°C and 60% relative humidity, and component 2 is an acidifying agent. One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof for dilution and contains no more than 5% total impurities during a 6-month storage period at 25°C and 60% relative humidity, and component 2 is an acidifying agent. One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof for dilution and contains no more than 4% total impurities during a 6-month storage period at 25°C and 60% relative humidity, and component 2 is an acidifying agent. One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof for dilution and contains no more than 3% total impurities during a 6-month storage period at 25°C and 60% relative humidity, and component 2 is an acidifying agent. One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof for dilution and contains no more than 2% total impurities during a 6-month storage period at 25°C and 60% relative humidity, and component 2 is an acidifying agent. One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof for dilution and contains no more than 1.5% total impurities during a 6-month storage period at 25°C and 60% relative humidity, and component 2 is an acidifying agent. One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof for dilution and contains no more than 1% total impurities during a 6-month storage period at 25°C and 60% relative humidity, and component 2 is an acidifying agent. One embodiment of the present invention provides a method of administering a reconstituted diluent solution, comprising mixing component 1 and component 2 to form a reconstituted diluent solution, and then diluting the reconstituted diluent solution with an infusion vehicle, wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharmaceutically acceptable salt thereof for dilution and contains no more than 0.5% total impurities during a 6-month storage period at 25°C and 60% relative humidity, and component 2 is an acidifying agent. The following examples are given for the purpose of illustrating the present invention and should not be construed as limiting the scope of the invention. [Example]
[0056] Carfilzomib formulation
[0057] [Table 1] procedure: 1. A portion of dimethylacetamide was placed in a container, and carfilzomib was weighed and added to it, followed by mixing with continuous stirring under a nitrogen purge and a sodium vapor lamp. 2. Dehydrated alcohol was added to the above solvent system and mixed until a clear solution was obtained. 3. With continuous stirring, the orthophosphoric acid was measured and added and mixed well. 4. Make up the final volume with dimethylacetamide and mix well until a homogenous solution is obtained. 5. The product was filtered through a 0.22μ filter and filled into vials. [Example]
[0058] Carfilzomib formulation
[0059] [Table 2] procedure: 1. Propylene glycol and polysorbate 80 were mixed at 2-8°C for 10 minutes. 2. Alpha tocopherol was added to the above mixture. 3. The pH of the solution was adjusted to 3-4 (3.5) using lactic acid. 4.3 The mixture of carfilzomib and dimethylacetamide was added and mixed until a clear solution was formed. 5. Nitrogen purging and light protection were maintained throughout the batch preparation at 2-8°C. 6. The product was filtered at 0.22μ, filled into vials and sealed.
[0060] Example 2A: Preparation of carfilzomib formulations Example 2A was prepared in the same manner as Example 2.
[0061] [Table 3] Example 2B: Preparation of carfilzomib formulations Example 2B was prepared in the same manner as in Example 2.
[0062] [Table 4] Example 2C: Preparation of Carfilzomib Formulations Example 2C was prepared in the same manner as in Example 2.
[0063] [Table 5] [Example]
[0064] Carfilzomib formulation
[0065] [Table 6] procedure: 1. Dimethylacetamide and dehydrated alcohol were mixed homogeneously at room temperature under a nitrogen purge and a sodium vapor lamp. 2. Carfilzomib was added to the above solvent system and mixed until completely solubilized. 3. The product was filtered through a 0.22μ filter and filled into vials. [Example]
[0066] Carfilzomib formulation Formulations T1 to T4 were prepared in the same manner as in Example 3.
[0067] [Table 7] [Example]
[0068] Carfilzomib formulation
[0069] [Table 8] procedure: 1. Dimethylacetamide was placed in a suitable container and the temperature was maintained at 2-8°C. 2. Alpha tocopherol was added to step 1. 3. Carfilzomib was added to the DMA and tocopherol mixture from step 2 and mixed well until completely solubilized. 4. To the above 3, water for injection and polysorbate 80 were added and mixed well until uniformly dissolved. 5. The volume was adjusted using propylene glycol and mixed until a uniform solution was obtained. 6. The complete process was carried out under nitrogen purge and sodium vapor lamp. 7. The product was filtered through a 0.22μ filter and filled into vials.
[0070] Example 5A: Preparation of carfilzomib formulations Example 5A was prepared in the same manner as in Example 5.
[0071] [Table 9] Example 5B: Preparation of carfilzomib formulations Example 5B was prepared in the same manner as in Example 5.
[0072] [Table 10] Table 1: Stability of the formulations prepared in Examples 5A and 5B
[0073] [Table 11] [Example]
[0074] Carfilzomib formulation The formulations in this example were prepared according to the procedure described in Example 5.
[0075] [Table 12] Example 6A: Preparation of carfilzomib formulations
[0076] [Table 13] procedure 1. A sufficient amount of ethanol was collected in a preparation vessel. 2. The mass of α-tocopherol was added with continuous stirring until a homogeneous solution was obtained. The reading was recorded. 3. The mass of carfilzomib was added with continuous stirring until a homogenous solution was obtained. The description was recorded. 4. Ethanol was added to make up the final volume and stirred until a homogenous solution was obtained. 5. The bulk was filtered through a 0.22μ PTFE filter and filled into vials.
[0077] Example 6B: Preparation of carfilzomib formulations
[0078] [Table 14] procedure 1. A sufficient amount of N,N-dimethylacetamide was collected in a preparation vessel. 2. The required amount of α-tocopherol was added with continuous stirring until a homogeneous solution was obtained. The description was recorded. 3. The required amount of carfilzomib was added with continuous stirring until a homogeneous solution was obtained. 4. Ethanol was added to make up the final volume and stirred until a homogenous solution was obtained. 5. The bulk was filtered through a 0.22μ PTFE filter and filled into vials. [Example]
[0079] Table 2: Stability comparison of the formulations prepared in Examples 1, 2, 3, and 5
[0080] [Table 15] *RT room temperature (stability test parameters: temperature 25°C, relative humidity 60%), *ND: not detected, *NMT: not detected. [Example]
[0081] Preparation and stability data of injectable formulations containing acidifiers
[0082] [Table 16] procedure: The required amount of 1.80% dehydrated alcohol was collected in a clean container. 2. The required amount of carfilzomib was added to the solvent from step 1 at 2-8°C and dissolved with a mechanical stirrer until a clear solution was observed. 3. In step 2, the required amount of alpha tocopherol was added with stirring at 2-8°C until a clear solution was observed. 4. In step 3, the required amount of o-phosphoric acid was added with stirring at 2-8°C until a clear solution was observed. 5. Make up the final batch size with the required amount of dimethylacetamide and mix well at 2-8°C. 6. The bulk solution was filtered using a 0.2 micron PTFE filter. 7. Amber vials were filled, blanketed with nitrogen, and properly sealed with rubber stoppers. 8. The vials maintained heat stability at 25°C, 60% RH, and 2-8°C.
[0083] Table 3. Stability data of injectable formulation compositions containing acidifying agents
[0084] [Table 17] [Example]
[0085] Preparation and stability data of injectable formulation composition before and after mixing with acidifying agent
[0086] [Table 18] procedure: The required amount of 1.80% dehydrated alcohol was collected in a clean container. 2. In step 1, the required amount of carfilzomib was added at 2-8°C and dissolved with a mechanical stirrer until a clear solution was observed. 3. In step 2, the required amount of absolute ethanol was added with stirring at 2-8°C until a clear solution was observed. 4. Make up the final batch size with the required amount of dimethylacetamide and mix well at 2-8°C. 5. The bulk solution was filtered using a 0.2 micron PTFE filter. 6. Amber vials were filled, blanketed with nitrogen, and properly sealed with rubber stoppers. 7. The vials maintained heat stability at 25°C, 60% RH, and 2-8°C.
[0087] Table 4. Stability data of injectable formulation composition before mixing with acidifying agent
[0088] [Table 19] *NP = Not yet performed Table 5: Procedure for mixing acidifying agent into diluent composition
[0089] [Table 20] procedure: 1. Aseptically mix vial 1 and vial 2 as per Table 3 above. 2. Gently swirl or invert the vial for 1 minute. 3. Visually inspect for particulate matter and discoloration before mixing. The diluted solution should be colorless and transparent, and do not mix if discoloration or particulate matter is found. 4. The mixed product solution from step 3 was diluted with sterile water for injection to concentrations of 0.5 mg / ml and 1.5 mg / ml, and the solution stability was demonstrated at 25°C and 2-8°C.
[0090] Table 6. Stability data of injectable formulation compositions after mixing with an acidifier at concentrations of 0.5 mg / ml and 1.5 mg / ml
[0091] [Table 21] [Example]
[0092] Preparation and stability data of injectable formulation composition before and after mixing with acidifying agent
[0093] [Table 22] procedure: 1.80% of the required dimethylacetamide was collected in a clean, pure container. 2. In step 1, the required amount of carfilzomib was added at 2 to 8°C and dissolved using a mechanical stirrer. 3. Make up the final batch size with the required amount of dimethylacetamide and mix well at 2-8°C. 4. The bulk solution was filtered using a 0.2 micron PTFE filter. 5. Amber vials were filled, blanketed with nitrogen, and properly sealed with rubber stoppers. 6. The vials maintained thermal stability at 25°C, 60% RH, 2-8°C, and 40°C / 75% RH.
[0094] Table 7. Stability data of injectable formulation composition before mixing with acidifying agent
[0095] [Table 23] *ND = Not Detected Table 8. Procedure for mixing acidifying agent into diluent composition
[0096] [Table 24] procedure: 1) Aseptically mix vial 1 and vial 2 as shown in the table above. 2) Gently swirl or invert the vial for 1 minute. 3) Visually inspect for particulate matter and discoloration before mixing. The diluted solution should be colorless and transparent, and if discoloration or particulate matter is found, do not mix it with the injection medium. 4) The mixed product solution was diluted with sterile water for injection to concentrations of 0.5 mg / ml and 1.5 mg / ml, and the solution stability was demonstrated at 25°C and 2-8°C.
[0097] Table 9. Stability data of injectable formulation composition after mixing with 0.5 mg / ml and 1.5 mg / ml of acidifying agent
[0098] [Table 25] [Example]
[0099] Carfilzomib formulation
[0100] [Table 26] procedure: 1. A standard amount of N,N-dimethylacetamide was taken into a preparation vessel at a temperature of 2-8°C. 2. The batch amount of alpha tocopherol was metered in with continuous stirring until a homogenous solution was obtained. 3. The batch amount of carfilzomib was then weighed and added with continuous stirring until completely dissolved. 4. The batch quantity of water for injection was added with continuous stirring until a homogenous solution was obtained. 5. The batch amount of Polysorbate 80 was added with continuous stirring until a homogenous solution was obtained. 6. Ultra-purified PG was added to the final volume and stirred until a homogenous solution was obtained. 7. The bulk was filtered through a 0.22μ PTFE filter and filled into vials. [Example]
[0101] Carfilzomib formulation
[0102] [Table 27] procedure: 1. A standard amount of ethanol was taken into a preparation vessel at a temperature of 2-8°C. 2. The batch amount of alpha tocopherol was metered in with continuous stirring until a homogenous solution was obtained. 3. The batch amount of carfilzomib was then weighed and added with continuous stirring until completely dissolved. 4. The batch quantity of water for injection was added with continuous stirring until a homogenous solution was obtained. 5. The batch amount of Polysorbate 80 was added with continuous stirring until a homogenous solution was obtained. 6. Ultra-purified PG was added to the final volume and stirred until a homogenous solution was obtained. 7. The bulk was filtered through a 0.22μ PTFE filter and filled into vials. [Example]
[0103] Carfilzomib formulation
[0104] [Table 28] procedure: 1. A standard amount of dimethylacetamide was taken into a preparation vessel at a temperature of 2-8°C. 2. The batch amount of alpha tocopherol was metered in with continuous stirring until a homogenous solution was obtained. 3. The batch quantity of Polysorbate 80 was added with continuous stirring until completely dissolved. 4. The batch quantity of water for injection was added with continuous stirring until a homogenous solution was obtained. 5. The batch quantity of ultra-purified PG was added with continuous stirring until a homogenous solution was obtained. 6. The batch amount of carfilzomib was weighed and added with continuous stirring until a homogenous solution was obtained. 7. Ultra-purified PG was added to the final volume and stirred until a homogenous solution was obtained. 8. The bulk was filtered through a 0.22μ PTFE filter and filled into vials. [Example]
[0105] Carfilzomib formulation
[0106] [Table 29] procedure: 1. A standard amount of dimethylacetamide was taken into a preparation vessel at a temperature of 2-8°C. 2. The batch amount of alpha tocopherol was metered in with continuous stirring until a homogenous solution was obtained. 3. The batch quantity of Polysorbate 80 was added with continuous stirring until completely dissolved. 4. The batch quantity of water for injection was added with continuous stirring until a homogenous solution was obtained. 5. The batch quantity of ultra-purified PG was added with continuous stirring until a homogenous solution was obtained. 6. The batch amount of carfilzomib was weighed and added with continuous stirring until a homogenous solution was obtained. 7. Ultra-purified PG was added to the final volume and stirred until a homogenous solution was obtained. 8. The bulk was filtered through a 0.22μ PTFE filter and filled into vials. [Example]
[0107] Carfilzomib formulation
[0108] [Table 30] procedure: 1.90% N,N-dimethylacetamide was taken in a preparation vessel at a temperature of 2-8°C. 2. The batch amount of carfilzomib was weighed and added with continuous stirring until a homogenous solution was obtained. 3. N,N-dimethylacetamide was added to the final volume and stirred until a homogeneous solution was obtained. 4. The bulk was filtered through a 0.22μ PTFE filter and filled into vials. [Example]
[0109] Carfilzomib formulation
[0110] [Table 31] procedure: 1. A batch amount of N,N-dimethylacetamide was collected in a preparation vessel at a temperature of 2-8°C. 2. The batch amount of carfilzomib was weighed and added with continuous stirring until a homogenous solution was obtained. 3. Ethanol was added to the final volume and stirred until a homogeneous solution was obtained. 4. The bulk was filtered through a 0.22μ PTFE filter and filled into vials. [Example]
[0111] Carfilzomib formulation
[0112] [Table 32] procedure: 1.80% N,N-dimethylacetamide was taken in a preparation vessel at a temperature of 2-8°C. 2. The batch amount of carfilzomib was weighed and added with continuous stirring until a homogenous solution was obtained. 3. N,N-dimethylacetamide was added to the final volume and stirred until a homogeneous solution was obtained. 4. The bulk was filtered through a 0.22μ PTFE filter and filled into vials.
[0113] Table 10. Thermal stability and analytical results of APPL-006 / 01 / 105
[0114] [Table 33] NMT: Maximum ND - Not Detected [Example]
[0115] Carfilzomib formulation
[0116] [Table 34] procedure: 1. A batch amount of N,N-dimethylacetamide was collected in a preparation vessel at a temperature of 2-8°C. 2. The batch amount of carfilzomib was weighed and added with continuous stirring until a homogenous solution was obtained. 3. Ethanol was added to make up the final volume and stirred until a homogenous solution was obtained. 4. The bulk was filtered through a 0.22μ PTFE filter and filled into vials.
[0117] Table 11: Thermal stability and analytical results of APPL-006 / 01 / 106
[0118] [Table 35] NMT: Maximum ND - Not Detected
Claims
1. A room temperature stable ready to dilute injectable formulation comprising carfilzomib or a pharma- ceutically acceptable salt thereof and one or more solvents, wherein the total amount of impurities during a storage period of at least three months is 6% or less.
2. An injectable formulation for dilution stable at room temperature as described in claim 1, wherein the concentration of carfilzomib or a pharma- ceutically acceptable salt thereof is in the range of 10 mg / mL to 100 mg / mL.
3. An injectable formulation for dilution stable at room temperature as described in claim 1, wherein the concentration of carfilzomib or a pharma- ceutically acceptable salt thereof is in the range of 10 mg / mL to 60 mg / mL.
4. An injectable formulation for dilution stable at room temperature as described in claim 1, further comprising, optionally, one or more pharma- ceutically acceptable excipients selected from antioxidants, buffers, preservatives and surfactants.
5. An injectable formulation for dilution stable at room temperature as described in claim 1, having a total amount of impurities of 6% or less during a storage period of at least 6 months.
6. 2. The room temperature stable injectable formulation for dilution according to claim 1, comprising one or more solvents selected from ethanol, isopropyl alcohol, benzyl alcohol, propylene glycol polyethylene glycol, glycerol, dimethylacetamide, N-methylpyrrolidone, dimethylsulfoxide (DMSO), diethylene glycol monoethyl ether, caprylocaproyl polyoxyl-8 glyceride, glycofurol, or mixtures thereof.
7. The injectable formulation for dilution stable at room temperature described in claim 6, wherein the ratio of one or more solvents to carfilzomib or a pharma- ceutically acceptable salt thereof is 100:1 to 8:
1.
8. The antioxidant is selected from the group consisting of butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, and C-tocopherol, DL-tocopherol, C-tocopherol acetate, C-tocopherol tocopherol polyethylene glycol succinate (vitamin E TPGS), L-cysteine ascorbyl palmitate thioglycolate, sodium metabisulfite.
5. The room temperature stable injectable formulation for dilution according to claim 4, wherein the antioxidant is selected from one or more hydrophilic antioxidants including sodium thorium (SMBS), ascorbic acid, sodium formaldehyde sulfoxylate, or sodium EDTA and thioglycerol.
9. An injectable formulation for dilution stable at room temperature as described in claim 8, wherein the concentration of the antioxidant is present at a concentration of 0.005% by mass to 5% by mass of the total composition.
10. 2. The room temperature stable injectable formulation for dilution according to claim 1, comprising carfilzomib or a pharma- ceutically acceptable salt thereof and one or more solvents, and stored at 25°C and a relative humidity of 60% or at 40°C and a relative humidity of 75%.
11. 2. The injectable formulation for dilution stable at room temperature according to claim 1, wherein the total impurities contained during storage are 5% or less, 4% or less, 3% or less, 2% or less, 1.5% or less, 1% or less, or 0.5% or less.
12. 1. A ready to dilute formulation for treating a patient with relapsed or refractory multiple myeloma, comprising an injectable formulation stable at room temperature comprising carfilzomib or a pharma- ceutically acceptable salt thereof and one or more solvents, wherein the ready to dilute formulation has a total impurity content of 6% or less during a storage period of at least three months.
13. 13. The formulation for dilution according to claim 12, wherein the formulation for injection is stable when stored at 25°C and 60% relative humidity for 6 months.
14. A reconstituted ready-to-dilute injectable formulation for treating patients with relapsed or refractory multiple myeloma, wherein the reconstituted ready-to-dilute injectable formulation is reconstituted by mixing component 1 and component 2 and then diluted with an infusion vehicle, and wherein component 1 comprises a room temperature stable parenteral formulation of carfilzomib or a pharma- ceutically acceptable salt thereof, and wherein the total amount of impurities during a storage period of at least 3 months is 6% or less, and wherein component 2 is an acidifying agent.
15. The reconstituted injectable formulation for dilution described in claim 14, wherein the concentration of carfilzomib or a pharma- ceutically acceptable salt thereof is in the range of 10 mg / mL to 60 mg / mL.
16. The reconstituted injectable formulation for dilution described in claim 14, wherein the ratio of the amount (w / w) of the acidifying agent in component 2 to the amount of carfilzomib or a pharma- ceutically acceptable salt thereof in component 1 is from about 1:50 to about 1:
1.
17. The reconstituted injectable formulation for dilution described in claim 14, wherein component 1 comprises a room temperature stable parenteral dilution formulation of carfilzomib or a pharma- ceutically acceptable salt thereof having a total impurity content of 6% or less when stored for 6 months at 25°C and 60% relative humidity, and component 2 is an acidifying agent.
18. A reconstituted injectable formulation for dilution as described in claim 14, wherein component 1 is stored at 25°C and a relative humidity of 60% or at 40°C and a relative humidity of 75% for a period of at least 3 months.
19. 15. The reconstituted injectable formulation for dilution of claim 14, wherein component 1 contains less than 5%, less than 4%, less than 3%, less than 2%, less than 1.5%, less than 1%, or less than 0.5% total impurities when stored for 6 months at 25° C. and 60% relative humidity.
20. 15. The reconstituted injectable formulation for dilution of claim 14, comprising component 2 as an acidifying agent selected from citric acid, acetic acid, maleic acid, phosphoric acid, succinic acid, tartaric acid, ascorbic acid, benzenesulfonic acid, oxalic acid, fumaric acid, orthophosphoric acid, gluconic acid, malic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, lacturonic acid, lactic acid, lactobionic acid, edetic acid, gentisic acid, metaphosphoric acid, nitric acid, pentetic acid, glycolic acid, or mixtures thereof.
21. A reconstituted ready-to-dilute formulation for treating patients with relapsed or refractory multiple myeloma, comprising component 1 and component 2, which are mixed and reconstituted, and then diluted with an infusion vehicle, wherein component 1 is a room temperature stable parenteral dilution formulation of carfilzomib or a pharma- ceutically acceptable salt thereof, and component 2 is an acidifying agent, and the reconstituted ready-to-dilute formulation has a total impurity content of 2% or less up to 6 hours after mixing when stored at room temperature.
22. 22. The reconstituted formulation for dilution of claim 21, wherein total impurities are 1% or less for up to 6 hours, 2% or less for up to 5 hours, 1% or less for up to 5 hours, 2% or less for up to 4 hours, or 1% or less for up to 4 hours after mixing when stored at room temperature.
